Cardiac Effects of Growth Hormone in Physiology and in Heart Failure

Saccà, Luigi; Fazio, Serafino; Longobardi, Salvatore; Cittadini, Antonio

doi:10.1507/endocrj.46.suppl_s5

Cited by 5 publications

(3 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The somatotropic axis has been reported to influence blood pressure regulation via effects on the heart, vascular resistance or volaemia in patients with acromegaly, whereas its possible blood-pressure effects in hypopituitarism continue to be debated [37][38][39][40]. In our study, however, blood pressure was not related to either GH or to IGF-I in men, or in women from the general population.…”

Section: Discussioncontrasting

confidence: 73%

Evidence for distinct effects of GH and IGF‐I in the metabolic syndrome

et al. 2007

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 73%

Evidence for distinct effects of GH and IGF‐I in the metabolic syndrome

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Experimental evidence indicates that GH exerts a direct effect on structure and function by inducing mRNA expression for specifi c contractile proteins and myocyte hypertrophy (2) . Experimental evidence indicates that GH exerts a direct effect on structure and function by inducing mRNA expression for specifi c contractile proteins and myocyte hypertrophy (2) .…”

Section: Discussionmentioning

confidence: 99%

Congenital hypopituitarism presenting as dilated cardiomyopathy in a child

Jain

Kannan²,

Kumar³

2011

Journal of Pediatric Endocrinology and Metabolism

View full text Add to dashboard Cite

Congenital hypopituitarism is commonly diagnosed either in infancy with neonatal hypoglycemia, prolonged jaundice and/or microphallus or in early to mid-childhood because of short stature. Replacement of defi cient hormones allows the affected children to have a normal and productive life. We describe a 10-year-old boy with congenital hypopituitarism whose parents fi rst sought defi nitive medical attention when the child developed congestive heart failure due to dilated cardiomyopathy, presumably secondary to prolonged untreated central hypothyroidism and growth hormone defi ciency.

show abstract

“…[1][2][3][4] Endothelial cells possess high-affinity IGF-1 receptors and release nitric oxide (NO) when stimulated by IGF-1, 5 and IGF-1 thus appears to be an important stimulus for endothelium-dependent vasodilatation. 1,3,6 In human patients with heart failure (HF), an inverse relationship between degree of HF and circulating concentrations of IGF-1 has been found in several, [7][8][9] but not all, 10,11 studies. In severe HF, GH resistance characterized by high concentrations of GH and low concentrations of IGF-1 in plasma or serum often develops, especially if body mass index is decreased or frank cachexia has developed.…”

mentioning

confidence: 99%

Circulating Concentrations of Insulin‐Like Growth Factor‐1 in Dogs with Naturally Occurring Mitral Regurgitation

Pedersen

Falk

Häggström

et al. 2005

Veterinary Internal Medicne

View full text Add to dashboard Cite

Insulin-like growth factor-1 (IGF-1), which mediates most effects of growth hormone, has effects on cardiac mass and function, and plays an important role in the regulation of vascular tone. In humans, an inverse relationship between degree of heart failure (HF) and circulating IGF-1 concentrations has been found in several studies. In dogs with HF, few studies have focused on IGF-1. We examined circulating IGF-1 concentrations in dogs with mitral regurgitation (MR) caused by myxomatous mitral valve disease. Study 1 included 88 Cavalier King Charles Spaniels (CKCSs) with a broad range of asymptomatic MR (median serum IGF-1: 76.7 microg/L; 25-75 percentile, 59.8-104.9 microg/L). As expected, standard body weight and percentage under- or overweight correlated directly with IGF-1. MR (assessed in 4 different ways) did not correlate with IGF-1. In study 2, 28 dogs with severe MR and stable, treated congestive HF had similar serum IGF-1 concentrations (median, 100.8 g/L; 25-75 percentile, 74.9-156.5 microg/L) as 11 control dogs (79.6 microg/L; 25-75 percentile, 64.1-187.4 microg/L; P = .84). In study 3, the plasma IGF-1 concentration of 15 untreated CKCSs with severe MR was 16.4 +/- 24.2 microg/L lower (P = .02) at the examination when decompensated HF had developed (80.8 +/- 30.9 microg/L) than at a visit 1-12 months earlier (97.2 +/- 39.8 microg/L), possibly in part due to an altered state of nutrition. The studies document that circulating IGF-1 concentrations are not altered before development of congestive HF in dogs with naturally occurring MR, but decrease by approximately 20% with the development of untreated HE In treated HF, circulating IGF-1 concentrations apparently return to within the reference range.

show abstract

Cardiac Effects of Growth Hormone in Physiology and in Heart Failure

Cited by 5 publications

References 32 publications

Evidence for distinct effects of GH and IGF‐I in the metabolic syndrome

Evidence for distinct effects of GH and IGF‐I in the metabolic syndrome

Congenital hypopituitarism presenting as dilated cardiomyopathy in a child

Circulating Concentrations of Insulin‐Like Growth Factor‐1 in Dogs with Naturally Occurring Mitral Regurgitation

Contact Info

Product

Resources

About